The introduction of immunotherapy with ICIs for the treatment of NSCLC in selected patients with positive PD-L1 expression has produced a significant improvement in survival for those patients associated with a substantial reduction in grade 3–4 toxicity. Here, CD274 is linked to non-small cell lung carcinoma.